Misplaced Pages

This is an old revision of this page, as edited by Beetstra (talk | contribs) at 09:17, 25 October 2011 (Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'CAS_number').). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Gaboxadol

Clinical data
ATC code	none
Identifiers
IUPAC name 4,5,6,7-tetrahydroisoxazolopyridin-3(2H)-one
PubChem CID	3448
ChemSpider	3330
UNII	K1M5RVL18S
KEGG	D04282
ChEMBL	ChEMBL312443
CompTox Dashboard (EPA)	DTXSID0045206
ECHA InfoCard	100.059.039
Chemical and physical data
Formula	C6H8N2O2
Molar mass	140.14 g/mol g·mol
3D model (JSmol)	Interactive image
SMILES O=C1/C2=C(\ON1)CNCC2
InChI InChI=1S/C6H8N2O2/c9-6-4-1-2-7-3-5(4)10-8-6/h7H,1-3H2,(H,8,9) Key:ZXRVKCBLGJOCEE-UHFFFAOYSA-N
(what is this?)  (verify)

Gaboxadol also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) is an experimental sleep aid drug developed by Lundbeck and Merck. In March, 2007, Merck and H. Lundbeck cancelled work on the drug, citing safety concerns and the failure of an efficacy trial. It acts on the GABA system, but in a very different way from benzodiazepines and Z-drugs (zolpidem, zaleplon, etc). Lundbeck states that gaboxadol also increases deep sleep (stage 4).

See also

• Muscimol

References

1. US Patent 4278676 - Heterocyclic compounds

External links

• 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
• H. Lundbeck Website
• Medical News Today article
• Report of cancellation of development.

This sedative-related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Sedatives
• Lactams
• Sedative stubs